Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post marketing study of Fantom

Trial Profile

A post marketing study of Fantom

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2018 According to a REVA Medical media release, the first Fantom Encore has been implanted in this study
    • 27 Aug 2018 New trial record
    • 07 Aug 2018 According to a REVA Medical media release, the first patient was enrolled in May and the Company is working to add new hospitals to the study
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top